33 results about "Gastrointestinal absorption" patented technology

The invention relates to a drug sustained release microsphere for injection and a preparation method thereof. The preparation is a sustained-release microsphere injection, the prepared microspheres are narrower in particle size distribution, high in encapsulation efficiency and small in burst release rate, the drug can be continuously released for four weeks to six weeks, a better administration route is provided for patients with poor gastrointestinal absorption, and meanwhile, the drug tolerance and toxic and side effects can be reduced. The preparation method comprises the following steps: adding a cosolvent, and adjusting the proportion of a medicinal active component and a biocompatible high polymer material in an organic solvent, the mass percentage of the cosolvent and the organic solvent, the mass percentage concentration of a surfactant in an external water phase, and the proportion of the mass of the organic solvent and the mass of the external water phase, so as to prepare the biocompatible high polymer material. The microsphere preparation containing the active pharmaceutical ingredients is obtained in an emulsification mode, the burst release rate in vitro within 24 hours is lower than 10%, the encapsulation efficiency is high, the preparation method is simple, and the microsphere preparation can be suitable for industrialization of the production process of the microsphere preparation.

The invention belongs to the technical field of medicines, and discloses a betahistine mesylate oral soluble film agent for treating meniere disease, meniere syndrome and vertigo symptoms caused by vertigo and a preparation process thereof, the preparation process comprises the following steps: (1) adding betahistine mesylate into purified water; (2) adding glycerol, citric acid, sucralose, liquid orange-flavored essence and sunset yellow into the raw material medicine solution; (3) taking HPMC-E15, dispersing the HPMC-E15 in purified water, and adding HPC-LXF for thickening; (4) adding the medicine-containing solution into the blank glue solution; (5) degassing; (6) coating; and (7) cutting and packaging. Compared with a common tablet, the oral soluble film disclosed by the invention has a higher release rate, and can enter a body through a sublingual vein way in addition to a conventional gastrointestinal tract absorption way after being dissolved in an oral cavity, so that the bioavailability is increased; under the condition of stability acceleration, the compound has a better impurity level, and the preparation process is simple to operate, high in repeatability and suitable for industrial large-scale production.

The application relates to the technical field of biological medicine, and particularly provides a pharmaceutical composition containing a peptide drug active molecule and an application thereof. The pharmaceutical composition comprises a peptide drug active molecule and a drug delivery molecule, and the weight ratio of the peptide drug active molecule to the drug delivery molecule is 1:(1-500); the drug delivery molecule is selected from a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof. The application provides an application of the pharmaceutical composition in preparing an oral dosage form drug. The peptide drug active molecule is significantly improved in stability and permeability in a gastrointestinal fluid by being compounded with the drug delivery molecule, so that gastrointestinal absorption of the peptide drug active molecule is increased and oral bioavailability of the peptide drug active molecule is improved.

The application discloses a pirfenidone nanosuspension inhalation solution for treating interstitial pneumonia and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The pirfenidone nanosuspension inhalation solution is composed of the following components in 1000ml: 8-12g of pirfenidone hydrochloride, 4-6g of polyethylene glycol-poly-L-histidine block copolymer, 45-55g of mannitol, 0.4-0.6g of antioxidant, 0.05mol / L of citric acid-sodium citrate buffer, and water for injection, wherein the amount of the citric acid-sodium citrate buffer is appropriate, and the water for injection is added to 1000ml. The application adopts a pulmonary targeted inhalation administration path of non-gastrointestinal absorption, so that the drug directly acts on the lung interstitial lesion part by bypassing the intestinal absorption link.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The invention discloses an upatinib gel plaster and a preparation method thereof, the gel plaster can improve the skin transmittance, absorptivity and stability of an upatinib gel composition through the combination of sorbitol and propylene glycol and the compounding of other components such as a penetration enhancer. The traditional Chinese medicine composition is used for treating psoriasis and arthritis, can be directly adhered to an affected part for administration, is convenient to use, reduces the influence of a gastrointestinal tract absorption way on the medicine, reduces toxic and side effects of gastrointestinal tract administration, is large in medicine loading capacity and long in acting time, and does not pollute clothes. The developed Upatinib gel plaster fills up the market blank, is convenient for patients to take, and has a wide market prospect.

The application discloses methyl phenolic compounds, a preparation method and application thereof. Six new methyl phenolic compounds are separated from the skin of eleocharis tuberosa, and the compounds all show good inhibitory activity on alpha-glucosidase, and are stronger than the clinical first-line drug acarbose. The inhibitory activity of compound 3 is the best, enzyme kinetics research shows that the compound 3 plays a role as a reversible mixed inhibitor, ADME predicts that the compound 3 has good drug properties, including high gastrointestinal absorption and no CYP450 enzyme inhibition. The cytotoxicity experiment shows that the six compounds have no obvious growth inhibition on human embryonic kidney cells HEK293 at a concentration of 100 muM, and have good safety. The compounds can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, and are used for preparing a health care product for reducing blood sugar or a drug for treating diabetes. The preparation method is simple, easy to operate, suitable for industrial production, and is helpful to the high-value reuse of the skin of eleocharis tuberosa.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and / or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and / or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.

The application belongs to the technical field of plant genetic engineering, and particularly relates to a millet gene Seita.8G189900 and Seita.8G190200 application in controlling prolamine quality. The nucleotide sequence of the millet gene Seita.8G189900 is shown as SEQ ID NO. 1, and the nucleotide sequence of the millet gene Seita.8G190200 is shown as SEQ ID NO. 2. The application proves two genes that can down-regulate the content of prolamine in millet, and the prolamine content of millet can be reduced by reducing the expression level of the genes. Knocking out the two genes can not only down-regulate the content of prolamine, but also up-regulate the content of amino acid, increase the nutritional value of millet, and be more beneficial to gastrointestinal absorption and digestion, thereby providing a new gene resource for protein quality improvement.

The present disclosure belongs to the field of biomedicine, and specifically relates to an oral polypeptide composition for improving the gastrointestinal absorption of polypeptide drugs. Specifically, it discloses an oral polypeptide composition, and the composition comprises polypeptide molecules, medium-chain fatty acids (MCFA) and their salts, amino acids and N-(8- (2-hydroxybenzoyl) amino) caprylic acid (NAC) and its salts. The oral polypeptide composition of this disclosure can effectively increase the plasma drug concentration of the polypeptide and improve the oral bioavailability of the polypeptide.

The invention relates to the technical field of nutritious sports food, and discloses cashew nut and sea cucumber peptide exercise recovery powder and a method, the cashew nut and sea cucumber peptide exercise recovery powder comprises the following components by mass: 40%-55% of a composite peptide composition, 25%-35% of a rapid energy supply matrix, 5%-10% of an anti-inflammatory active component, and 10%-15% of a synergistic auxiliary agent, the composite peptide composition is formed by compounding a cashew nut extract and sea cucumber peptide according to a mass ratio of (4-6): (3-5), the molecular weight distribution of the cashew nut extract is 200-800Da, the purity of the cashew nut extract is greater than or equal to 92%, the molecular weight distribution of the sea cucumber peptide is 300-1000Da, the purity of the sea cucumber peptide is greater than or equal to 90%, the rapid energy supply matrix is formed by compounding maltodextrin and fructo-oligosaccharide according to a mass ratio of (3-4): 1, and the anti-inflammatory active component comprises curcumin microcapsules and resveratrol. Through the specific compounding design of the cashew nut extract and the sea cucumber peptide, in combination with precise molecular weight control, advantage complementation of amino acid composition is achieved, and the gastrointestinal tract absorption efficiency of nutritional ingredients is remarkably improved in cooperation with a targeted slow release technology of curcumin microcapsules.

The invention discloses a ginsenoside glutathione liposome as well as a preparation method and application thereof, and particularly provides the ginsenoside glutathione liposome which is characterized in that raw materials of the ginsenoside glutathione liposome comprise the following components in percentage by mass: 15%-20% of glutathione, 5%-10% of ginsenoside, 35%-40% of sunflower lecithin and 35%-40% of maltodextrin. The mass fraction refers to the mass percentage of each component in the raw materials. The ginsenoside glutathione liposome provided by the invention is stable in property, controllable in particle size, high in drug encapsulation efficiency, good in drug stability, high in bioavailability and gastrointestinal absorption rate and reasonable in compatibility; the preparation process is relatively good, the preparation conditions are easy to realize, and industrialization is facilitated; the optimization of the combination of the preparation process and the product performance is realized.

An oral polypeptide composition for improving the gastrointestinal absorption of polypeptide drugs is provided. The oral polypeptide composition includes polypeptide molecules, medium-chain fatty acids (MCFA) and their salts, amino acids and N-(8-(2-hydroxybenzoyl) amino) caprylic acid (NAC) and its salts. The oral polypeptide composition can effectively increase the plasma drug concentration of the polypeptide and improve the oral bioavailability of the polypeptide.

The invention relates to the technical field of biological medicine, and particularly provides a pharmaceutical composition containing peptide drug active molecules and application of the pharmaceutical composition. The pharmaceutical composition comprises peptide drug active molecules and drug delivery molecules, wherein the weight ratio of the peptide drug active molecules to the drug delivery molecules is 1: (1-500); the drug delivery molecule is selected from a structure represented by a formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses application of the pharmaceutical composition in preparation of oral dosage form medicines. According to the present invention, the peptide drug active molecule is compounded with the drug delivery molecule, such that the stability and the permeability of the peptide drug active component in the gastrointestinal fluid are significantly improved so as to increase the absorption in the intestines and the stomach and improve the oral bioavailability of the peptide drug active component;

The invention provides phosphatidylated pseudo-ginseng micro powder, soluble powder and a preparation method, and particularly belongs to the technical field of medicines. The invention provides phospholipid pseudo-ginseng micro powder. The phospholipid pseudo-ginseng micro powder is prepared from the following raw materials in parts by weight: 180 to 220 parts of pseudo-ginseng micro powder, 10 to 20 parts of phospholipid, 5 to 25 parts of mesoporous auxiliary material, 150 to 260 parts of glyceryl stearate and 10 to 50 parts of pore-foaming agent. The phosphatidylated pseudo-ginseng micro powder can effectively cover bitter taste of pseudo-ginseng and improve gastrointestinal absorption of pseudo-ginseng, has high bioavailability and high stability, and can be used for preventing and treating cardiovascular diseases.

The invention discloses a potassium-supplementing special diet as well as a preparation method and application thereof. The potassium-supplementing special diet is mainly prepared from the following substances in parts by weight: 42 to 43.5 parts of trehalose, 24 to 26 parts of potassium, 13 to 17 parts of dietary fiber, 9 to 11 parts of konjaku flour, 1.6 to 3 parts of acidulant, 1.5 to 1.8 parts of inorganic salt, 0.3 to 0.4 part of L-ascorbic acid, 0.005 to 0.008 part of riboflavin, 0.005 to 0.015 part of thiamine nitrate, 1.8 to 2.0 parts of food essence and 0.19 to 0.25 part of sweetening agent. The potassium-supplementing special diet provided by the invention promotes gastrointestinal absorption, greatly increases the compliance of patients, is suitable for long-term potassium supplement, can reduce the irritation of potassium chloride to gastrointestinal tracts to the minimum, enables the potassium chloride to have small side effects, and can supplement sufficient potassium by adopting special diet official documents.

The invention discloses a ginseng composition beverage capable of promoting gastrointestinal absorption and a preparation method and application thereof, and belongs to the technical field of foods.The ginseng composition beverage capable of promoting gastrointestinal absorption is prepared from ginsenoside extract, phospholipid substances and cyclodextrin; the ginsenoside extract comprises ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1; the ginsenoside extract and the phospholipid substance are combined through a hydrogen bond to form a hydrogen bond conjugate system; the hydrogen bond conjugate system and cyclodextrin form an inclusion compound through an inclusion effect. The functional components ginsenoside Rg1, Re and Rb1 in the ginseng are taken as indexes, the solubility, fat solubility and stability of the three kinds of ginsenoside are improved at the same time at a time, gastrointestinal absorption of the ginseng can be promoted, the ginseng can be better utilized, and the efficacy of the ginseng can be better exerted.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

The invention belongs to the technical field of soybean milk powder, and particularly relates to a dendrobium-containing soybean milk powder composition which comprises the following components: 70-85% of soybean milk powder, 3-10% of a dendrobium extract, 5-15% of maltose and 2-8% of fructo-oligosaccharide, and specifically comprises the following components: 70% of soybean milk powder, 10% of a dendrobium extract, 12% of maltose and 8% of fructo-oligosaccharide. The dendrobium extract is an extract obtained by water extraction of dendrobium stems, and the solid content is 20-50%; in the dendrobium-containing soybean milk powder composition disclosed by the invention, the soybeans provide high-quality protein and soy isoflavone; the dendrobe extract is rich in dendrobe polysaccharide and alkaloid, so that the immune regulation capability of a body can be remarkably enhanced, and the gastrointestinal absorption function is improved; the fructo-oligosaccharide serving as prebiotics can promote reproduction of beneficial bacteria in intestinal tracts and improve the micro-ecological environment of the intestinal tracts.

This invention relates to the field of traditional Chinese medicine preparation technology, specifically to a blood-activating and meridian-clearing traditional Chinese medicine composition with agarwood as the principal ingredient. The composition comprises the following raw materials in parts by weight: 5-15 parts modified agarwood complex, 40-60 parts compound extract powder, 1-3 parts broken-cell-wall scorpion powder, 20-50 parts filler, and 0.5-2 parts lubricant. This invention improves the efficient release of the effective components of agarwood as the principal ingredient by using the modified agarwood complex, ensuring the stability of the core efficacy of agarwood and extending the retention time of its core components. The addition of compound extract powder scientifically combines blood-activating and blood-nourishing herbs, ensuring powerful meridian clearing while replenishing qi and blood, reducing the side effects of long-term medication, and improving patient safety. The broken-cell-wall scorpion powder reduces the risk of sensitization and poisoning, breaking the cell walls of the scorpion to fully release the core analgesic peptides and antithrombotic peptides, thus improving gastrointestinal absorption efficiency.

The present disclosure belongs to the field of biological medicine, and particularly relates to an oral polypeptide composition for improving gastrointestinal absorption of polypeptide drugs; and particularly discloses an oral polypeptide composition, which comprises polypeptide molecules, medium-chain fatty acids and salts thereof, amino acids, and N-(8-(2-hydroxybenzoyl)amino)octanoic acid (NAC) and salts thereof. The oral polypeptide preparation of the present disclosure can effectively improve the blood drug concentration of polypeptides, and improve the bioavailability of oral polypeptides.

The invention belongs to the technical field of food processing, and provides a horse milk powder nutritional composition which is prepared from the following components in parts by weight: 45-55 parts of horse milk powder, 8-12 parts of a gordon euryale seed extract, 3-7 parts of a sea-buckthorn extract, 8-12 parts of a hawthorn extract, 3-7 parts of soybean oligosaccharides and 3-7 parts of xylooligosaccharides. After the nutritional composition of the horse milk powder is given to spleen-deficiency model rats, the urine D-xylose discharge amount and the serum AMS content of the rats are remarkably increased, the spleen and thymus indexes are remarkably increased, and the IgM and IgG expression in the serum is remarkably increased, so that the nutritional composition of the horse milk powder remarkably improves the gastrointestinal absorption function and enhances the immune function, and has a wide application prospect.

The invention relates to application of a gastric retention shape memory composite membrane. The gastric retention shape memory composite membrane is prepared by the following method: (1) mixing a polymer with dichloromethane to obtain a solution 1; (2) preparing a solution 2 by taking water as a solvent, wherein the solution 2 contains hydroxypropyl methyl cellulose and NaHCO3; and (3) mixing the solution 1 and the solution 2, stirring, adding the luteolin phospholipid complex, continuously stirring, and volatilizing dichloromethane and water. The gastro-retention shape memory composite membrane provided by the invention can be used for preparing a medicine for treating gastric cancer, has a good in-vivo expansion effect, has the deformation temperature closer to the temperature of a human body, and can enhance the permeation of luteolin to a biological membrane, improve the gastrointestinal absorption effect of luteolin, reduce stomach discomfort of a patient and improve the bioavailability of the medicine.

The invention discloses a soft capsule for improving an anxiety state as well as a preparation method and application of the soft capsule, and belongs to the technical field of pharmaceutical preparations. Comprising contents and a capsule shell wrapping the contents. The content consists of a compound extract, phospholipid and emotional fish oil. The compound extract is prepared from bupleurum chinense, salvia miltiorrhiza, cape jasmine, angelica sinensis, bighead atractylodes rhizome, poria cocos, dried ginger, mint and liquorice; the capsule shell comprises chitosan, sodium alginate, a rosemary extract microcapsule, vitamin C palmitate, titanium dioxide, pachymaran and the like, and the rosemary extract microcapsule is prepared from a rosemary extract through pachymaran microencapsulation. Through the synergistic effect of all the components, the compatibility of the compound extract and the emotional fish oil is effectively improved, the stability of an oil phase system is improved, the oxidative rancidity risk of the emotional fish oil is reduced, meanwhile, the emotional fish oil is matched with the gastrointestinal absorption characteristics of people with weakness of the spleen and the stomach, and a pharmaceutical preparation choice is provided for conditioning the anxiety state.

The invention relates to a gastric retention shape memory composite membrane. The gastric retention shape memory composite membrane is prepared by the following method: (1) mixing a polymer with dichloromethane to obtain a solution 1; (2) preparing a solution 2 by taking water as a solvent, wherein the solution 2 contains hydroxypropyl methyl cellulose and NaHCO3; and (3) mixing the solution 1 and the solution 2, stirring, adding the luteolin phospholipid complex, continuously stirring, and volatilizing dichloromethane and water. The gastro-retention shape memory composite membrane provided by the invention has a good in-vivo expansion effect, the deformation temperature of the gastro-retention shape memory composite membrane is closer to the temperature of a human body, and the gastro-retention shape memory composite membrane can enhance penetration of luteolin to a biological membrane, improve the gastrointestinal absorption effect of the luteolin, reduce stomach discomfort of a patient and improve the bioavailability of a medicine.

The invention relates to the technical field of milk powder formulas, in particular to novel goat milk infant formula milk powder and a preparation method thereof. Comprising the following raw materials: 40% to 80% of raw goat milk, 6% to 10% of desalted goat whey powder, 1.6% to 2.4% of vegetable oil, 0.4% to 0.8% of lactose, 0.2% to 0.3% of galactooligosaccharide, 0.1% to 0.3% of fructo-oligosaccharide, 0.02% to 0.06% of docosahexaenoic acid, 0.02% to 0.06% of arachidonic acid, 0.01% to 0.04% of bifidobacterium, 0.01% to 0.04% of rhamnose lactic acid bacteria, 0.01% to 0.02% of lactoferrin, 0.01% to 0.03% of L-carnitine, 0.1% to 0.3% of a vitamin premixing bag and 0.1% to 0.3% of a mineral substance premixing bag. According to the present invention, the probiotic powder contains the metabiotics and the sufficient number of the three probiotics and the sufficient number of the two prebiotics, such that the bottleneck problem that the traditional probiotics do not resist the high temperature and the gastric acid and cannot directly reach the human intestinal tract is solved; the composition can directly and rapidly act on human bodies through intestinal barriers, can promote gastrointestinal absorption of infants, and improves immunity of the infants.

The invention belongs to the technical field of biological medicines, and discloses a plant nano-vesicle loaded with siRNA, a siRNA delivery system of the plant nano-vesicle and application of the plant nano-vesicle in preparation of medicines for preventing and / or treating myocardial fibrosis. According to the application disclosed by the invention, the BNC2 is used as a myocardial fibrosis treatment target for the first time, the activation of myocardial fibroblasts and the expression of fibrosis-related factors are effectively inhibited by inhibiting the expression of the BNC2, and a new molecular target is provided for myocardial remodeling intervention after myocardial infarction. The invention further provides an efficient siRNA nano delivery system capable of being delivered orally, specifically, the safflower-derived nano vesicles are used as a delivery platform, have the capacity of being absorbed through gastrointestinal tracts and enriching heart tissue in a targeted mode, and are loaded with siRNA targeting BNC2, expression of mRNA of the BNC2 gene can be remarkably inhibited, myocardial fibrosis activity can be effectively inhibited, myocardial fibrosis reaction can be inhibited, and the application prospect is wide. The compound can be applied to preparation of drugs for preventing and / or treating myocardial fibrosis.

The invention discloses a ginsenoside coenzyme Q10 liposome as well as a preparation method and application thereof. The invention provides a ginsenoside coenzyme Q10 liposome which comprises the following components in parts by mass: 1 part of coenzyme Q10, 0.3-0.5 part of ginsenoside Rx, 1-3 parts of sunflower lecithin and 1.5-3 parts of maltodextrin, and the mass ratio of sunflower lecithin to maltodextrin is 1: (1-3). Wherein the ginsenoside Rx is a ginsenoside mixture, and the ginsenoside Rx comprises 20 (S)-ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rk1; the ginsenoside coenzyme Q10 liposome disclosed by the invention does not contain cholesterol. The ginsenoside coenzyme Q10 liposome disclosed by the invention has better bioavailability; compared with the conventional cholesterol coenzyme Q10, the gastrointestinal absorption of the coenzyme Q10 is improved by more than 1.9 times.

The present invention relates to, for oral delivery of biodrugs, a multi-arm polyethylene glycol-KLA peptide conjugate, a PEGylated distearoyl phosphatidylethanolamine-KLA peptide conjugate, a PAMAM dendrimer-KLAL peptide conjugate, and a composition for enhancing absorption, in the gastrointestinal tract, of a biodrug for oral administration containing same as oral absorption enhancers, the conjugates of the present invention reducing cytotoxicity due to the cell permeable properties of a KLA peptide, and maintaining a tight junction modulation function of KLA through effects such as increasing resistance to proteolytic enzymes in the gastrointestinal tract, so as to promote gastrointestinal absorption of biodrugs such as peptides, proteins, polysaccharides, and antibodies when orally administrated, and thus being able to be usefully employed in increasing the bioavailability of a drug.